Szpital Uniwersytecki W Krakowie
- Address
- ul. M. Jakubowskiego 2, 30-688 Krakow, Poland
Szpital Uniwersytecki W Krakowie - Neurological Research Center
Szpital Uniwersytecki W Krakowie (University Hospital in Kraków) is a leading academic medical center conducting advanced clinical research in neurological disorders. The institution demonstrates particular expertise in neurodegenerative diseases and acute cerebrovascular conditions, participating in innovative trials evaluating novel therapeutic interventions for conditions affecting cognitive function and stroke management.
- Alzheimer's Disease and Mild Cognitive Impairment: Investigating pharmacokinetics, pharmacodynamics, and safety profiles of emerging treatments for cognitive decline
- Acute Ischemic Stroke: Evaluating novel thrombolytic agents and advanced interventional approaches including endovascular thrombectomy
- Neuropharmacology: Conducting comprehensive safety and tolerability assessments of innovative neurological therapeutics
The center's research portfolio reflects a commitment to addressing critical unmet needs in neurological care, from early-stage cognitive impairment through acute cerebrovascular emergencies. Through rigorous placebo-controlled, randomized trials, the institution contributes to advancing therapeutic options for patients with debilitating neurological conditions while maintaining the highest standards of clinical research methodology and patient safety protocols.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Care Arthritis Ltd.2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Uniwersytecki W Krakowie
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE) | Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE | 2 | Unknown | 2026-01-22 | 2026-07-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.